| Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer L Barault, A Amatu, G Siravegna, A Ponzetti, S Moran, A Cassingena, ... Gut 67 (11), 1995-2005, 2018 | 234 | 2018 |
| Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer L Barault, A Amatu, FE Bleeker, C Moutinho, C Falcomatà, V Fiano, ... Annals of oncology 26 (9), 1994-1999, 2015 | 130 | 2015 |
| Context-specific determinants of the immunosuppressive tumor microenvironment in pancreatic cancer C Falcomatà, S Bärthel, G Schneider, R Rad, M Schmidt-Supprian, ... Cancer Discovery 13 (2), 278-297, 2023 | 91 | 2023 |
| Selective multi-kinase inhibition sensitizes mesenchymal pancreatic cancer to immune checkpoint blockade by remodeling the tumor microenvironment C Falcomata, S Baerthel, SA Widholz, C Schneeweis, JJ Montero, ... Nature Cancer 3 (3), 318-336, 2022 | 80 | 2022 |
| Decrypting drug actions and protein modifications by dose-and time-resolved proteomics J Zecha, FP Bayer, S Wiechmann, J Woortman, N Berner, J Müller, ... Science 380 (6640), 93-101, 2023 | 57 | 2023 |
| Single-cell profiling to explore pancreatic cancer heterogeneity, plasticity and response to therapy S Bärthel, C Falcomatà, R Rad, FJ Theis, D Saur Nature cancer 4 (4), 454-467, 2023 | 52 | 2023 |
| Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment C Riganti, MF Lingua, IC Salaroglio, C Falcomatà, L Righi, D Morena, ... Oncoimmunology 7 (3), e1398874, 2018 | 51 | 2018 |
| Mass spectrometry-based draft of the mouse proteome P Giansanti, P Samaras, Y Bian, C Meng, A Coluccio, M Frejno, ... Nature methods 19 (7), 803-811, 2022 | 44 | 2022 |
| Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal … A Sartore-Bianchi, F Pietrantonio, A Amatu, M Milione, A Cassingena, ... European Journal of Cancer 71, 43-50, 2017 | 36 | 2017 |
| Pancreatic cancer intrinsic PI3Kα activity accelerates metastasis and rewires macrophage component B Thibault, F Ramos‐Delgado, E Pons‐Tostivint, N Therville, C Cintas, ... EMBO molecular medicine 13 (7), e13502, 2021 | 31 | 2021 |
| CRISPR somatic genome engineering and cancer modeling in the mouse pancreas and liver T Kaltenbacher, J Löprich, R Maresch, J Weber, S Müller, R Oellinger, ... Nature Protocols 17 (4), 1142-1188, 2022 | 21 | 2022 |
| Genetic Screens Identify a Context-Specific PI3K/p27Kip1 Node Driving Extrahepatic Biliary Cancer C Falcomatà, S Bärthel, A Ulrich, S Diersch, C Veltkamp, L Rad, F Boniolo, ... Cancer discovery 11 (12), 3158-3177, 2021 | 20 | 2021 |
| Hematopoietic aging promotes cancer by fueling IL-1⍺–driven emergency myelopoiesis MD Park, J Le Berichel, P Hamon, CM Wilk, M Belabed, N Yatim, A Saffon, ... Science 386 (6720), eadn0327, 2024 | 18 | 2024 |
| Non-canonical functions of SNAIL drive context-specific cancer progression MC Paul, C Schneeweis, C Falcomatà, C Shan, D Rossmeisl, S Koutsouli, ... Nature Communications 14 (1), 1201, 2023 | 18 | 2023 |
| Cell-selective proteomics segregates pancreatic cancer subtypes by extracellular proteins in tumors and circulation JJ Swietlik, S Bärthel, C Falcomatà, D Fink, A Sinha, J Cheng, S Ebner, ... Nature Communications 14 (1), 2642, 2023 | 13 | 2023 |
| AP1/Fra1 confers resistance to MAPK cascade inhibition in pancreatic cancer C Schneeweis, S Diersch, Z Hassan, L Krauß, C Schneider, D Lucarelli, ... Cellular and Molecular Life Sciences 80 (1), 12, 2023 | 9 | 2023 |
| New insights into pancreatic cancer: notes from a virtual meeting E Hessmann, G Schneider, C Bousquet, C Der, S Dreyer, N Dusetti, ... Gastroenterology 161 (3), 785-791, 2021 | 6 | 2021 |
| Personalizing KRAS-Mutant Allele–Specific Therapies C Falcomatà, G Schneider, D Saur Cancer Discovery 10 (1), 23-25, 2020 | 6 | 2020 |
| Ovarian cancer-derived IL-4 promotes immunotherapy resistance G Mollaoglu, A Tepper, C Falcomatà, HT Potak, L Pia, A Amabile, ... Cell 187 (26), 7492-7510. e22, 2024 | 4 | 2024 |
| Dual Recombinase–Based Mouse Models Help Decipher Cancer Biology and Targets for Therapy T Sket, C Falcomatà, D Saur Cancer Research 83 (14), 2279-2282, 2023 | 4 | 2023 |
